Effects of Alendronate on Bone Quality and Remodeling in Glucocorticoid-Induced Osteoporosis: A Histomorphometric Analysis of Transiliac Biopsies

Oxford University Press (OUP) - Tập 15 Số 4 - Trang 754-762 - 2000
Pascale Chavassieux1, M. Arlot1, Jean‐Paul Roux1, Nathalie Portero1, Anastasia G. Daifotis2, A J Yates2, Neveen A. T. Hamdy3, Marie‐Pierre Malice4, Debra Freedholm2, Jean Sibilia1
1INSERM Unité 403, Faculté de Médecine R. T. H. Laënnec, Lyon, France.
2Merck Research Laboratories, Rahway, New Jersey U.S.A.
3Leiden University Medical Center, Leiden, The Netherlands.
4Merck Sharp and Dohme, Brussels, Belgium.

Tóm tắt

Abstract Effects of alendronate (ALN) on bone quality and turnover were assessed in 88 patients (52 women and 36 men aged 22–75 years) who received long-term oral glucocorticoid exposure. Patients were randomized to receive oral placebo or alendronate 2.5, 5, or 10 mg/day for 1 year and stratified according to the duration of their prior glucocorticoid treatment. Transiliac bone biopsies were obtained for qualitative and quantitative analysis after tetracycline double-labeling at the end of 1 year of treatment. As previously reported in glucocorticoid-induced osteoporosis, low cancellous bone volume and wall thickness were noted in the placebo group as compared with normal values. Alendronate treatment was not associated with any qualitative abnormalities. Quantitative comparisons among the four treatment groups were performed after adjustment for age, gender, and steroid exposure. Alendronate did not impair mineralization at any dose as assessed by mineralization rate. Osteoid thickness (O.Th) and volume (OV/BV) were significantly lower in alendronate-treated patients, irrespective of the dose (P = 0.0003 and 0.01, respectively, for O.Th and OV/BV); however, mineral apposition rate was not altered. As anticipated, significant decreases of mineralizing surfaces (76% pooled alendronate group; P = 0.006), activation frequency (–72%; P = 0.004), and bone formation rate (–71%; P = 0.005) were also noted with alendronate treatment. No significant difference was noted between the changes observed with each dose. Absence of tetracycline label in trabecular bone was noted in approximately 4% of biopsies in placebo and alendronate-treated groups. Trabecular bone volume, parameters of microarchitecture, and resorption did not differ significantly between groups. In conclusion, alendronate treatment in patients on glucocorticoids decreased the rate of bone turnover, but did not completely suppress bone remodeling and maintained normal mineralization at all alendronate doses studied. Alendronate treatment did not influence the osteoblastic activity, which is already low in glucocorticoid-induced osteoporosis.

Từ khóa


Tài liệu tham khảo

Saag, 1994, Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events, Am J Med, 96, 115, 10.1016/0002-9343(94)90131-7

Meunier, 1984, Glucocorticoid EffectsTheir Biological Consequences, 191

Dempster, 1989, Bone histomorphometry in glucocorticoid-induced osteoporosis, J Bone Miner Res, 4, 137, 10.1002/jbmr.5650040202

Luckert, 1996, Osteoporosis, 801

Bressot, 1979, Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis, Calcif Tissue Int, 1, 303

Meunier, 1993, Is steroid-induced osteoporosis preventable?, N Engl J Med, 328, 1781, 10.1056/NEJM199306173282411

Fleisch, 1998, Bisphosphonates: Mechanisms of action, Endocr Rev, 19, 80, 10.1210/edrv.19.1.0325

Liberman, 1995, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis, N Engl J Med, 333, 1437, 10.1056/NEJM199511303332201

Black, 1996, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2

McClung, 1998, Alendronate prevents postmenopausal bone loss in women without osteoporosis: A double-blind, randomized, controlled trial, Ann Intern Med, 28, 523

Hosking, 1998, Prevention of bone loss with alendronate in postmenopausal women under 60 years of age, N Engl J Med, 338, 485, 10.1056/NEJM199802193380801

Adami, 1995, Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis, Bone, 17, 383, 10.1016/S8756-3282(95)00262-6

Chesnut, 1995, Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling, Am J Med, 99, 144, 10.1016/S0002-9343(99)80134-X

Devogelaer, 1996, Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis, Bone, 18, 141, 10.1016/8756-3282(95)00436-X

Tucci, 1996, Effect of three-years of oral alendronate treatment in postmenopausal women with osteoporosis, Am J Med, 101, 488, 10.1016/S0002-9343(96)00282-3

Karpf, 1997, Prevention of nonvertebral fractures by alendronate: A meta-analysis, JAMA, 277, 1159, 10.1001/jama.1997.03540380073035

Cummings, 1998, Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial, JAMA, 280, 2077, 10.1001/jama.280.24.2077

Pols, 1999, A multinational, placebo-controlled randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study, Osteoporos Int, 9, 461, 10.1007/PL00004171

Chavassieux, 1997, Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis, J Clin Invest, 100, 1475, 10.1172/JCI119668

Bone, 1997, Dose-response relationships for alendronate treatment in osteoporotic elderly women, J Clin Endocrinol Metab, 82, 265

Garnero, 1994, Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment, J Clin Endocrinol Metab, 79, 1693

Saag, 1998, Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis, N Engl J Med, 339, 292, 10.1056/NEJM199807303390502

Parfitt, 1987, Bone histomorphometry: Standardization of nomenclature, symbols, and units, J Bone Miner Res, 2, 595, 10.1002/jbmr.5650020617

Roux, 1995, Automatic interactive measurement of resorption cavities in transiliac bone biopsies and correlation with deoxypyridinoline, Bone, 17, 153, 10.1016/S8756-3282(95)00174-3

Parfitt, 1983, Bone Histomorphometry: TechniquesInterpretations, 143

Chavassieux, 1985, Intermethod variation in bone histomorphometry: Comparison between manual and computerized methods applied to iliac bone biopsies, Bone, 6, 221, 10.1016/8756-3282(85)90004-3

Dempster, 1983, Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis, Calcif Tissue Int, 35, 410, 10.1007/BF02405069

Meunier, 1973, Proceedings of the First Workshop on Bone Morphometry, 100

Vedi, 1982, Histomorphometric analysis of bone biopsies from the iliac crest of normal British subjects, Metab Bone Dis Rel Res, 4, 231, 10.1016/0221-8747(82)90032-7

Lips, 1978, Mean wall thickness of trabecular packets in the human iliac crest: Changes with age, Calcif Tissue Res, 26, 13, 10.1007/BF02013227

Melsen, 1978, Tetracycline double labeling of iliac trabecular bone in 41 normal adults, Calcif Tissue Res, 26, 99, 10.1007/BF02013242

Manolagas, 1999, New developments in the pathogenesis and treatment of steroid-induced osteoporosis, J Bone Miner Res, 14, 1061, 10.1359/jbmr.1999.14.7.1061

Chappard, 1996, Altered trabecular architecture induced by corticosteroids: A bone histomorphometric study, J Bone Miner Res, 11, 676, 10.1002/jbmr.5650110516

Parfitt, 1992, Disorders of BoneMineral Metabolism, 475

Parfitt, 1990, Metabolic Bone DiseaseRelated Disorders, 329

Reid, 1996, Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized placebo-controlled trial, Am J Med, 171, 341, 10.1016/S0002-9343(96)00227-6

Siris, 1996, Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone, J Clin Endocrinol Metab, 81, 961

Stock, 1997, Increment in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women, Am J Med, 103, 291, 10.1016/S0002-9343(97)00130-7

Balena, 1993, The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates, J Clin Invest, 92, 2577, 10.1172/JCI116872

Meunier, 1997, Bone mineral reflects bone mass but also the degree of mineralization of bone: therapeutic implications, Bone, 21, 373, 10.1016/S8756-3282(97)00170-1

Roschger, 1997, Mineralization of cancellous bone after alendronate and sodium fluoride treatment: A quantitative backscattered electron imaging study on minipig ribs, Bone, 20, 393, 10.1016/S8756-3282(97)00018-5

Boivin, 1998, Alendronate increases the mean degree of mineralization of bone and the uniformity of mineralization of bone in osteoporotic women, Bone, 23, F282

Thông tin
Thông tin xuất bản

Oxford University Press (OUP)

Tập 15 Số 4

754-762

Thông tin tác giả